Emerging innovation towards safety in the clinical application of ESCs and iPSCs

Nature Reviews Cardiology

Volumn 11, Issue 9, 2014, Pages 553-554

  Masuda, Shigeo ^a   Miyagawa, Shigeru ^a   Fukushima, Satsuki ^a   Sougawa, Nagako ^a   Ito, Emiko ^a   Takeda, Maki ^a   Saito, Atsuhiro ^a   Sawa, Yoshiki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; JC 011; METFORMIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SSEA 5; OCTAMER TRANSCRIPTION FACTOR 4; OLEIC ACID; PLURIPOTENT CELL SPECIFIC INHIBITOR; PROTEIN INHIBITOR; SEPANTRONIUM BROMIDE; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; CELL DIFFERENTIATION; DRUG MECHANISM; EMBRYONIC STEM CELL; ENDOPLASMIC RETICULUM STRESS; HUMAN; LETTER; LIPID METABOLISM; MALIGNANT TRANSFORMATION; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL TRANSPLANTATION; SYNTHESIS; TERATOMA;

CELL- AND TISSUE-BASED THERAPY; HEART DISEASES; HUMANS;

EID: 84906938965     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2014.9-c1     Document Type: Letter

References (16)

1. Behfar, A. et al. Cell therapy for cardiac repair-lessons from clinical trials. Nat. Rev. Cardiol. 11, 232-246 (2014).
2. Sawa, Y. & Miyagawa, S. Present and future perspectives on cell sheet-based myocardial regeneration therapy. Biomed. Res Int. http://dx.doi.org/10.1155/2013/583912.
3. Masuda, S. & Hanazon o, Y. Induced pluripotent stem cells in long-QT syndrome. N. Engl. J. Med. 364, 181-182 (2011).
4. Lee M. O., et al Inhibition of pluripotent stem cell-derived teratoma formation by small molecules. Proc. Natl Acad. Sci. USA 110, E3281-E3290 2013).
5. Blum, B. et al. The anti-Apoptotic gene survivin contributes to teratoma formation by human embryonic stem cells. Nat. Biotechnol. 27, 281-287 (2009).
6. Ben-David, U. et al. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell 12, 167-179 (2013).
7. Li, W., Li, K., Wei, W. & Ding, S. Chemical approaches to stem cell biology and therapeutics. Cell Stem Cell 13, 270-283 (2013).
8. Pernicova, I. & Korbonits, M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat. Rev. Endocrinol. 10, 143-156 (2014).
9. Vazquez-Martin, A. et al. Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency. Sci. Rep. 2, 964 (2012).
10. Vazquez-Martin, A. et al. Activation of AMP-Activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells. Cell Cycle 11, 974-989 (2012).
11. Tang, C. et al. An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat. Biotechnol. 29, 829-834 (2011).
12. Richards, M. et al. A new class of pluripotent stem cell cytotoxic small molecules. PLoS ONE 9, e85039 (2014).
13. Masuda, S. et al. A simplified in vitro teratoma assay for pluripotent stem cells injected into rodent fetal organs. Cell Med. 3, 103-112 (2012).
14. Lee, A. S. et al. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat. Med. 19, 998-1004 (2013).
15. Ben-David, U. & Benvenisty, N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat. Rev. Cancer 11, 268-277 (2011).
16. Herszfeld, D. et al. CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells. Nat. Biotechnol. 24, 351-357 (2006).